{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T02:41:11Z","timestamp":1791081671664,"version":"4.1.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2008,5,1]],"date-time":"2008-05-01T00:00:00Z","timestamp":1209600000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2008,5]]},"DOI":"10.1016\/j.ygyno.2008.01.009","type":"journal-article","created":{"date-parts":[[2008,3,5]],"date-time":"2008-03-05T13:08:19Z","timestamp":1204722499000},"page":"182-186","source":"Crossref","is-referenced-by-count":192,"title":["A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: A Gynecologic Oncology Group study"],"prefix":"10.1016","volume":"109","author":[{"given":"Susan C.","family":"Modesitt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Sill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James S.","family":"Hoffman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David P.","family":"Bender","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2008.01.009_bib1","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3322\/canjclin.57.1.43","article-title":"Cancer statistics, 2007","volume":"57","author":"Jemal","year":"2007","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ygyno.2008.01.009_bib2","first-page":"5165","article-title":"Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo","volume":"60","author":"Butler","year":"2000","journal-title":"Cancer Res"},{"key":"10.1016\/j.ygyno.2008.01.009_bib3","doi-asserted-by":"crossref","first-page":"11700","DOI":"10.1073\/pnas.182372299","article-title":"The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin","volume":"99","author":"Butler","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ygyno.2008.01.009_bib4","first-page":"539","article-title":"Histone deacetylase inhibitors enhance paclitaxel-induced cell death in ovarian cancer cell lines independent of p53 status","volume":"24","author":"Chobanian","year":"2004","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ygyno.2008.01.009_bib5","first-page":"217","article-title":"The combined in vitro effects of paclitaxel and histone deacetylase inhibitors on ovarian cancer","volume":"44","author":"Desimone","year":"2003","journal-title":"Proc Am Assoc Cancer Res"},{"key":"10.1016\/j.ygyno.2008.01.009_bib6","first-page":"S149","article-title":"Suberoylanilide hydroxamic acid potentiates paclitaxel-induced apoptosis in ovarian cancer cell lines","volume":"101","author":"Dietrich","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2008.01.009_bib7","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1089\/10507250152039046","article-title":"Histone deacetylase inhibitors promote apoptosis and differential cell cycle arrest in anaplastic thyroid cancer cells","volume":"11","author":"Greenberg","year":"2001","journal-title":"Thyroid"},{"key":"10.1016\/j.ygyno.2008.01.009_bib8","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1006\/bcmd.2000.0376","article-title":"Histone deacetylase inhibitors: development of suberoylanilide hydroxamic acid (SAHA) for the treatment of cancers","volume":"27","author":"Richon","year":"2001","journal-title":"Blood Cells Mol Dis"},{"key":"10.1016\/j.ygyno.2008.01.009_bib9","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/1471-2407-6-183","article-title":"Comparative evaluation of the treatment efficacy of suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer cell lines and primary ovarian cancer cells from patients","volume":"6","author":"Sonnemann","year":"2006","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ygyno.2008.01.009_bib10","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.canlet.2005.02.009","article-title":"Histone deacetylase inhibitors require caspase activity to induce apoptosis in lung and prostate carcinoma cells","volume":"232","author":"Sonnemann","year":"2006","journal-title":"Cancer Lett"},{"issue":"95 Suppl","key":"10.1016\/j.ygyno.2008.01.009_bib11","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1038\/sj.bjc.6603463","article-title":"Cancer biology: mechanism of antitumour action of vorinostat (suberoylanilide hydroxamic acid), a novel histone deacetylase inhibitor","volume":"1","author":"Richon","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ygyno.2008.01.009_bib12","article-title":"Phase II trial of oral suberoylanilide hydroxamic acid (SAHA) for cutaneous T-cell lymphoma (CTCL) and peripheral T-cell lymphoma (PTCL)","volume":"102","author":"Duvic","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.ygyno.2008.01.009_bib13","first-page":"3578","article-title":"Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously","volume":"9","author":"Kelly","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2008.01.009_bib14","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.ygyno.2006.09.011","article-title":"In vitro and in vivo histone deacetylase inhibitor therapy with suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer","volume":"104","author":"Cooper","year":"2007","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.ygyno.2008.01.009_bib15","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1006\/gyno.1997.4887","article-title":"Evaluation of cisplatin and cyclosporin A in recurrent platinum-resistant ovarian cancer: a phase II study of the Gynecologic Oncology Group","volume":"68","author":"Manetta","year":"1998","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2008.01.009_bib16","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1006\/gyno.1998.5016","article-title":"Altretamine (hexamethylmelamine) in platinum-resistant and platinum-refractory ovarian cancer: a Gynecologic Oncology Group phase II trial","volume":"69","author":"Markman","year":"1998","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.ygyno.2008.01.009_bib17","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/00000421-200202000-00009","article-title":"A phase II trial of pyrazoloacridine (PZA) in recurrent platinum-resistant ovarian cancer: a Gynecologic Oncology Group study","volume":"25","author":"Plaxe","year":"2002","journal-title":"Am J Clin Oncol"},{"issue":"12","key":"10.1016\/j.ygyno.2008.01.009_bib18","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.1200\/JCO.2001.19.12.2975","article-title":"Phase II study of paclitaxel and VALSPODAR (PSC 833) in refractory ovarian carcinoma: a Gynecologic Oncology Group study","volume":"19","author":"Fracasso","year":"2001","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ygyno.2008.01.009_bib19","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1006\/gyno.2000.5984","article-title":"Phase II trial of CI-958 in recurrent, platinum-refractory ovarian carcinoma: Gynecologic Oncology Group study","volume":"79","author":"Hoffman","year":"2000","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2008.01.009_bib20","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1006\/gyno.1999.5640","article-title":"Lack of efficacy of 24-hour infusional topotecan in platinum-refractory ovarian cancer: a Gynecologic Oncology Group trial","volume":"75","author":"Markman","year":"1999","journal-title":"Gynecol Oncol"},{"issue":"15","key":"10.1016\/j.ygyno.2008.01.009_bib21","doi-asserted-by":"crossref","first-page":"2856","DOI":"10.1200\/JCO.2003.03.077","article-title":"Phase II study of oxaliplatin in platinum resistant and refractory ovarian cancer: a Gynecologic Oncology Group study","volume":"21","author":"Fracasso","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2008.01.009_bib22","doi-asserted-by":"crossref","first-page":"2760","DOI":"10.1002\/cncr.20709","article-title":"Human ovarian carcinoma cells: histone deacetylase inhibitors exhibit antiproliferative activity and potently induce apoptosis","volume":"101","author":"Takai","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2008.01.009_bib23","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1002\/(SICI)1097-0258(19981030)17:20<2301::AID-SIM927>3.0.CO;2-X","article-title":"Optimal flexible designs in phase II clinical trials","volume":"17","author":"Chen","year":"1998","journal-title":"Stat Med"},{"key":"10.1016\/j.ygyno.2008.01.009_bib24","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/nrd2133","article-title":"Anticancer activities of histone deacetylase inhibitors","volume":"5","author":"Bolden","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.ygyno.2008.01.009_bib25","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/ncponc0106","article-title":"Drug insight: histone deacetylase inhibitors\u2014development of the new targeted anticancer agent suberoylanilide hydroxamic acid","volume":"2","author":"Kelly","year":"2005","journal-title":"Nat Clin Pract Oncol"},{"key":"10.1016\/j.ygyno.2008.01.009_bib26","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1196\/annals.1329.073","article-title":"Defining the chemotherapeutic targets of histone deacetylase inhibitors","volume":"1030","author":"Gabrielli","year":"2004","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.ygyno.2008.01.009_bib27","doi-asserted-by":"crossref","first-page":"3923","DOI":"10.1200\/JCO.2005.14.167","article-title":"Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer","volume":"23","author":"Kelly","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2008.01.009_bib28","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/PPO.0b013e31803c72ba","article-title":"Histone deacetylase inhibitors: biology and mechanism of action","volume":"13","author":"Mehnert","year":"2007","journal-title":"Cancer J"},{"key":"10.1016\/j.ygyno.2008.01.009_bib29","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1158\/1535-7163.MCT-06-0144","article-title":"Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation","volume":"6","author":"Marrocco","year":"2007","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ygyno.2008.01.009_bib30","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1182\/blood-2006-06-025999","article-title":"Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)","volume":"109","author":"Duvic","year":"2007","journal-title":"Blood"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825808000140?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825808000140?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,8]],"date-time":"2019-05-08T14:01:09Z","timestamp":1557324069000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825808000140"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,5]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008,5]]}},"alternative-id":["S0090825808000140"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2008.01.009","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2008,5]]}}}